Price$1.13-0.26 (-19.06%)
2026-04-212026-07-24
News · 26 weeks15+100%
2026-01-252026-07-19
Mix1290d
- SEC Filings9(75%)
- Other3(25%)
Latest news
25 items- SECSEC Form 424B3 filed by Bone Biologics Corp424B3 - Bone Biologics Corp (0001419554) (Filer)
- SECBone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 PrioritiesBURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (NASDAQ:BBLG, BBLGW)) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today issued a shareholder update summarizing the Company’s progress through the first half of 2026, including its recently completed financing, continued advancement of NB1, its rhNELL-1-based bone graft product candidate, and further validation of its manufacturing and product stability profile. "During the first half of 2026, we strengthened several of the fundamental drivers underlying NB1’s development and long-term value proposition: clinical execution, product stability, intellectual
- SECSEC Form DEFA14A filed by Bone Biologics CorpDEFA14A - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form S-3 filed by Bone Biologics CorpS-3 - Bone Biologics Corp (0001419554) (Filer)
- SECBone Biologics Corp filed SEC Form 8-K: Other Events8-K - Bone Biologics Corp (0001419554) (Filer)
- SECBone Biologics Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesBURLINGTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (NASDAQ:BBLG, BBLGW)) ("Bone Biologics," or the "Company"), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 2,112,677 shares of common stock (or pre-funded warrants in lieu thereof), Series F warrants to purchase up to 2,112,677 shares of common stock and short-term Series G warrants to purchase up to 2,112,677 shares of common stock at a purchase price of $1.42 per share of common stock (or per pre-funded warrant in lieu thereof) an
- SECSEC Form DEFA14A filed by Bone Biologics CorpDEFA14A - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form DEF 14A filed by Bone Biologics CorpDEF 14A - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the Company reported in December 2025. The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the Company progresses rhNELL-1 toward the manufacturing scale required for a future piv
- SECSEC Form 10-Q filed by Bone Biologics Corp10-Q - Bone Biologics Corp (0001419554) (Filer)
- SECBone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form 424B5 filed by Bone Biologics Corp424B5 - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form 10-K filed by Bone Biologics Corp10-K - Bone Biologics Corp (0001419554) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Walsh Deina H4 - Bone Biologics Corp (0001419554) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Frelick Jeff4 - Bone Biologics Corp (0001419554) (Issuer)
- SECBone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 OutlookBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. "We executed with discipline throughout 2025 as we focused on strengthening the foundation required to advance our clinical program," stated Bone Biologics CEO Jeff Frelick. "During the year, we made meaningful progress across product readiness, intellectual property, and capital structure, including extending the validated shelf life of our rhNELL-1 prot
- PRBone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 MonthsBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life milestones. Achieving a 24-month shelf life is expected to enhance manufacturing efficiency, inventory management, supply-chain flexibility, and clinical and commercial readiness as
- SECSEC Form 10-Q filed by Bone Biologics Corp10-Q - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form S-8 filed by Bone Biologics CorpS-8 - Bone Biologics Corp (0001419554) (Filer)
- SECBone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and OutlookBone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologics' development of NB1 and to review our expected milestones for the coming year, including the anticipated completion of enrollment in our first-in-human study and an interim update. As a reminder, NB1 consists of the recombinant human protein NELL-1 (rhNELL-1) combined with demineralized bone matrix (DBM). NELL-1 has several unique prope
- PRBone Biologics to Participate in the H.C. Wainwright Global Investment ConferenceBone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Bone Biologics Bone Biologics was founded to pursue regenerative medicine for bone. The Company is underta
BBLG FAQ
5 questionsWhat does Bone Biologics Corp do?
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic...Where does BBLG stock trade?
Bone Biologics Corp (BBLG) is listed on NASDAQ.What sector and industry is BBLG in?
Bone Biologics Corp operates in the Health Care sector, Industrial Specialties industry.What companies are similar to BBLG?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare BBLG side-by-side with any of them on Quantisnow.How can I track BBLG on Quantisnow?
Quantisnow aggregates Bone Biologics Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BBLG to receive live email and push alerts on every new disclosure.